Regulate California Now (@regulatecalnow) header
Regulate California Now (@regulatecalnow) profile picture

Non-partisan advocacy to promote state and municipal regulation for botanical kratom in California for adult consumers. Also cats. | https://teapawt.net/t.co/gZ89Gl63Gc

California, USA
Joined March 2026
Photo by Regulate California Now (@regulatecalnow)Photo by Regulate California Now (@regulatecalnow)Photo by Regulate California Now (@regulatecalnow)Photo by Regulate California Now (@regulatecalnow)Photo by Regulate California Now (@regulatecalnow)Photo by Regulate California Now (@regulatecalnow)Photo by Regulate California Now (@regulatecalnow)Photo by Regulate California Now (@regulatecalnow)Photo by Regulate California Now (@regulatecalnow)Photo by Regulate California Now (@regulatecalnow)
Was FedUp created for litigation purposes? While I don’t normally question recovery advocacy, this group has consistently attacked and marginalized those with pain, even going to far as to advocate for a ban on pain medications. Was it ever about addx? $ drugfreenj.org/blog/post/fed…
20
28
4
75
Regulate California Now retweeted
He is busy doing anything else, instead of passing judicial nominees. He has a bill to stop this, just waiting there on his committee: S.5383 literally called: The End Gas Station Heroin Act.
2day I spoke w parents whose children were harmed or killed by kratom Rebecca lost her son Robert less than 2 months ago at Ole Miss Tia lost her daughter Kielee in 2025 & Susan lost her son Matthew in 2021   Trump admin must act NOW 2protect American children frm deadly kratom
5
20
485
Regulate California Now retweeted
Replying to @ChuckGrassley
They didn’t. It combined two measures and quantified what DOJ was already calling “enforcement discretion” on extreme trace of MGPI. A defined measurement gives a clear threshold to all law enforcement, manufacturers, retailers, and consumers to know if their product is complaint or not. More products will be removed by the 100:1 requirement, that most media is ignoring, than the original standard without changing anything in practice on MGPI enforcement. The original standard was also ambiguous on what an “article” meant. A serving? A package? Bulk B2B SKUs? Individually wrapped servings in a multi-serving bag? The line between legal commerce and felony federal charges is not a place for ambiguity and will immediately raises questions about equitable enforcement.
3
11
134
Regulate California Now retweeted
In 2017, @DennisPrager wrote this heartbreaking article about a father who died by suicide after losing access to pain medication. Please read it. Nearly a decade later, we still don't know how many lives have been lost because our country has refused to track the patient outcome of drastic opioid reduction policies. Nobody denies opioids can cause harm. Why is there so little outrage over the suffering and deaths caused by taking them away? If you have a large platform, I am begging you to help bring attention to this. People are suffering. People are dying. How much longer will we look away? @DennisPrager @SuePrager @chicksonright @JillianMichaels @glennbeck @EdwinBlackBook @greggutfeld creators.com/read/dennis-pra…
11
86
8
198
4,418
Regulate California Now retweeted
Replying to @bariweiss
@bariweiss, @CBSNews, @CBS, @60Minutes, @jon_wertheim, AKA Demands CBS 60 Minutes Correct Major Errors November 17, 2026 American Kratom Association Demands CBS 60 Minutes Correct Major Errors and Explain Why Critical Scientific Evidence Was Omitted AKA challenges broadcast’s credibility after producers ignored pre-broadcast warnings, overlooked NMS Labs’ own toxicology advisory, failed to report NIH’s mitragynine research, and gave kratom critics extensive airtime without comparable scrutiny WASHINGTON, D.C. — November 17, 2026 — The American Kratom Association today demanded substantial corrections, an editorial review, and a meaningful on-air response to the November 15 60 Minutes broadcast on kratom, charging that the program presented a materially incomplete and misleading account of federal drug policy, forensic science, and the potential benefits and risks of natural botanical kratom. In an expanded formal letter to CBS News, the AKA identified significant factual errors and omissions that raise serious questions about the credibility and fairness of the broadcast. “60 Minutes had the actual federal regulatory documents. They had our detailed written responses. They had access to the latest forensic science. Yet viewers received a report that misstated the DEA’s threshold, ignored a critical second scheduling requirement, and omitted important evidence that did not fit the program’s narrative,” said Mac Haddow, Senior Fellow on Public Policy for the American Kratom Association. “That is not the level of investigative rigor the public should expect from 60 Minutes.” NMS Labs’ Own Advisory Raises Questions About the Broadcast’s Death Claims One of the AKA’s most serious concerns involves the interview with NMS Labs toxicologist Justin Brower. Brower told viewers that he had encountered numerous deaths attributed exclusively to kratom. But the broadcast did not explain NMS Labs’ recently published advisory, Mitragynine Alone No Longer Tells the Story: Rethinking Kratom Testing. The advisory warns that older or limited toxicology methods may fail to identify relevant compounds, including 7-hydroxymitragynine (7-OH) and mitragynine pseudoindoxyl (MGPI), potentially affecting the interpretation of kratom-related deaths. It calls for comprehensive quantitative testing that distinguishes individual alkaloids and accounts for their chemical instability, possible conversion during analysis, and interactions with other substances. “The laboratory represented as a leading authority in the program has itself published a warning that mitragynine-only testing is no longer sufficient to characterize many kratom-related exposures,” Haddow stated. “Why wasn’t that critical scientific qualification explained to viewers?” The AKA acknowledges that it does not know whether Brower’s interview occurred before or after the NMS advisory was published, or whether he discussed those limitations during portions of the interview that did not air. The Association is requesting that CBS clarify those questions. The omission is particularly significant because the program also interviewed forensic scientist Alex Krotulski, coauthor of an October 2026 study documenting serious analytical challenges involving 7-OH, MGPI, and related compounds. That research found that 7-OH concentrations in refrigerated blood declined by 89% over 112 days, accompanied by increased MGPI concentrations. “Families deserve accurate conclusions about the deaths of their loved ones. They should not be led to believe that older toxicology results definitively establish natural kratom as the cause when critical compounds may not have been adequately tested,” Haddow said. The AKA is calling for scientifically justified reassessment of historical cases where inadequate testing or retained evidence raises legitimate questions about the original conclusions. NIH’s June 1 Announcement Directly Contradicts the Impression That Mitragynine Has No Serious Scientific Therapeutic Potential The AKA also challenges the broadcast’s failure to report a significant announcement from the National Institutes of Health. On June 1, 2026, NIH announced that its Investigational New Drug application for purified mitragynine had taken effect with FDA, allowing federal researchers to begin Phase I human safety research evaluating the compound as a potential treatment for opioid use disorder. The broadcast instead presented kratom’s possible role in opioid withdrawal largely as a disputed industry claim and featured Dr. Andrew Kolodny dismissing its therapeutic prospects. “The federal government’s own scientists are investigating purified mitragynine as a possible opioid use disorder treatment, yet that major development was missing from a national broadcast questioning whether kratom has any legitimate potential benefit,” Haddow said. “That is an extraordinary omission.” The AKA emphasizes that the NIH announcement does not establish that mitragynine is effective for opioid use disorder or that FDA has approved kratom as a treatment. It does, however, demonstrate that NIH considers the compound sufficiently promising for controlled human research following preclinical investigation. “Viewers deserved to know that this was an active federal scientific research question — not simply a marketing claim made by kratom advocates,” Haddow added. Why Were Industry Relationships Scrutinized on One Side but Not the Other? The AKA also questioned the broadcast’s extensive treatment of lobbying expenditures and alleged political influence. The Association disclosed more than $14 million in state and federal lobbying expenditures from 2016 through 2025 in its November 11 response to CBS, explaining that the money supported consumer protection legislation, manufacturing requirements, labeling standards, age restrictions, and continued access to natural botanical kratom. Yet the program did not present a comparable accounting of lobbying and political activity by manufacturers seeking to preserve the market for concentrated 7-OH products. Nor did it place the AKA’s expenditures in the context of lobbying throughout the healthcare industry. Pharmaceutical and health-products interests spent approximately $452 million on federal lobbying in 2025, according to OpenSecrets-derived data. “If 60 Minutes intends to follow the money, it should follow all of the money — not selectively investigate advocacy for natural kratom while overlooking competing commercial interests,” Haddow said. The Association also called for consistent scrutiny of potential economic interests in the addiction treatment and recovery industry, including any relevant relationships between treatment providers, pharmaceutical companies, and experts advocating particular drug-policy positions. AKA Questions Incomplete Disclosure of Dr. Andrew Kolodny’s Professional and Financial Relationships The broadcast featured Dr. Andrew Kolodny as a prominent critic of natural kratom but provided limited information about his professional relationships in the addiction treatment field. Kolodny previously served as Chief Medical Officer of Phoenix House, a national addiction treatment organization. He has supported the development of buprenorphine treatment programs and has served as a paid expert witness in opioid-related litigation. Those relationships are publicly documented. The AKA is not asserting that Kolodny has any continued undisclosed financial interest in Suboxone’s manufacturer or in promoting its products. It is asking why his relevant professional and compensated activities did not receive the same degree of examination applied to kratom-associated researchers and advocates. “Dr. Kolodny is entitled to his opinions. But when 60 Minutes questions the credibility of people who support natural kratom because of their industry relationships, the program should apply comparable disclosure standards to experts who oppose it,” Haddow said. “Credibility requires consistent standards, not selective scrutiny.” CBS Made a Tenfold Error in Describing the DEA Scheduling Proposal The AKA further identified a clear factual error in the broadcast’s statement that the federal government increased the permitted 7-OH concentration by 20-fold. The original DEA concentration threshold was 0.5 milligrams per gram. The revised October threshold is 1 milligram per gram. That is a twofold increase — not twentyfold. The program also failed to adequately explain that the revised DEA proposal counts 7-OH and MGPI together under a single concentration limit and adds an independent requirement that the ratio of mitragynine to the combined opioid-active compounds must not fall below 100-to-1. Failure of either proposed requirement would trigger Schedule I controls. The AKA provided these facts to CBS four days before the broadcast. “The mathematical error is serious. But the failure to explain the actual two-part scheduling rule is even more consequential because it distorted the public’s understanding of what the federal government proposed,” Haddow said. Critics Received Extensive Airtime While AKA’s Detailed Written Response Was Reduced to a Passing Reference CBS contacted the AKA on November 6 with five questions concerning kratom policy, lobbying, and political influence. The Association responded in an eight-page letter on November 11 and expressed interest in participating in an on-air interview. No such AKA interview appeared in the broadcast. Instead, critics received extensive speaking opportunities while the AKA’s substantive written response was largely absent. The program also highlighted Haddow’s decades-old ethics convictions while presenting an edited excerpt of his congressional testimony concerning the absence of an established lethal dose of natural botanical kratom. The AKA is requesting review of the complete footage and the context of those statements. “60 Minutes questioned our credibility while declining to give viewers a comparable opportunity to hear our explanations directly,” Haddow said. “When a program directly attacks an organization’s credibility, it should not treat a detailed written response as merely a procedural formality.” AKA Demands Corrections, an Editorial Review, and an On-Air Opportunity to Respond The Association’s formal letter requests that CBS: • Correct the erroneous 20-fold statement and explain the complete DEA scheduling framework. • Address NMS Labs’ advisory and the limitations of historical mitragynine-only forensic testing. • Explain why NIH’s June 1 announcement concerning mitragynine research was omitted. • Review the treatment of lobbying expenditures and the disclosure of relevant relationships involving interview subjects. • Clarify the distinction between kratom-associated deaths and deaths proven to involve natural botanical kratom as a causal factor. • Publish the AKA’s complete November 11 response and provide a meaningful opportunity for an on-air interview. The AKA is also requesting that CBS review the broadcast’s characterization of FDA Import Alert 54-15 and the full context of edited statements attributed to its representatives. “The credibility of 60 Minutes will ultimately be measured by what it does now that these factual errors and omissions have been brought directly to its attention,” Haddow concluded. “Families deserve accurate forensic science. Consumers deserve truthful information. Policymakers deserve a complete explanation of federal regulations. And the American public deserves an investigative news program that follows the evidence even when the evidence complicates its narrative.” “CBS News should correct the record, explain what happened in its editorial review, and demonstrate that 60 Minutes holds itself to the same standards of accuracy, transparency, and accountability that it demands from everyone else.” Principal Supporting Sources CBS News, November 15, 2026: cbsnews.com/news/kratom-60-m… NMS Labs — Rethinking Kratom Testing: nmslabs.com/resources/educat… NIH — June 1, 2026, Mitragynine Research Announcement: beta.nih.gov/news-and-media/… DEA — October 14, 2026, Federal Register Notice: federalregister.gov/d/2026-2… Eccarius et al., Journal of Analytical Toxicology (2026): doi.org/10.1093/jat/bkag090 About the American Kratom Association The American Kratom Association is a consumer advocacy organization committed to protecting access to safe, natural kratom leaf products and advancing science-based consumer protection standards. AKA supports age restrictions, accurate labeling, contaminant testing, good manufacturing practices, and strong enforcement against adulterated, mislabeled, synthetic, semi-synthetic, concentrated, fortified, or chemically manipulated products falsely marketed as kratom. ‍americankratom.org/news/aka-…
18
41
6
130
6,063
Regulate California Now retweeted
As we watch the “kratom epidemic” being manufactured right before our eyes, let's take a look at some remarkable similarities to the messaging surrounding the “opioid crisis.” Same expert. Different product. Same playbook. A sneak peek at my upcoming investigative video on kratom and mass-tort litigation. Wait until you see the rest. If you missed part 1, here it is: youtu.be/5snBaswabII?si=VJ89… Dr. Andrew Kolodny's Messaging:
7
37
5
106
3,140
Regulate California Now retweeted
Replying to @60Minutes
@60Minutes @jon_wertheim I expected considerably more scientific rigor from a program with your reputation. Your reporting presents kratom as though traditional botanical products, standardized mitragynine extracts, and chemically converted 7-OH tablets belong in one interchangeable risk category. They do not. Your segment cites more than 5,000 overdose deaths involving kratom. Yet the critical scientific questions receive inadequate attention: How many involved multiple substances? Which formulations were consumed? What were the exposure levels? Was causation established? A 2026 CDC analysis found that 79% of 233 kratom-associated deaths reported to poison centers involved multiple substances. That doesn’t eliminate genuine risks, but it demonstrates why context matters. You also featured Dr. Andrew Kolodny comparing kratom’s effects to heroin and fentanyl. Opioid-receptor activity alone does not establish equivalent pharmacological potency, respiratory-depression risk, or overdose liability. The families featured deserve compassion and answers. Their tragedies also deserve rigorous scientific investigation—not a narrative that treats an entire botanical category as pharmacologically identical. Where was the meaningful discussion of FDA regulatory pathways, manufacturing standards, product-specific toxicology, or the distinction between traditional mitragynine products and concentrated 7-OH? I’m a botanical manufacturer who supports FDA oversight, GMP compliance, independent testing, and restrictions on chemically converted 7-OH. Consumer protection and consumer choice are not mutually exclusive. Your audience deserved a balanced scientific investigation, not a presentation that repeatedly emphasized the most alarming evidence while giving insufficient attention to the distinctions necessary to interpret it. The difference between journalism and advocacy is the willingness to challenge your own narrative. #Kratom #60Minutes #ScienceMatters #FDA #ConsumerProtection
Kratom products line shelves in thousands of gas stations, smoke shops, and convenience stores around the country. It’s an opioid that’s legal in most states. Experts told 60 Minutes that kratom can be addictive and has led to death in some cases. @jon_wertheim reports, Sunday.
6
16
1
57
950
Regulate California Now retweeted
Replying to @Twolfrecovery
Be sure to tell everyone you work for @GoodDrugPolicy an organization of @learnaboutsam who promoted the Q8 campaign to repeal legal cannabis in MA that voters rejected 75-25%, a 20 point increases in support in 10 years with no community in the state having a majority supporting it. DEA has given notice of intent to schedule synthetic derivative 7-OH and the already scheduled MGPI, MGM-15/16. I support this. HHS rejected calls to schedule botanical kratom in 2018. WHO Expert Committee on Drug Dependence under the UN Single Convention in 2021. Their risk profile and addiction liability are very different. Your difficulties do not negate the millions of Americans such as myself who use botanical kratom (or in the past Rx opioids) responsibly, safely, and to great success. I accepted the risk of dependence which I knew was a possibility within 30 seconds of finding out what it was. It isn’t some secret or hard to discover. For a medical procedure I reduced to zero from 20 grams/day in 31 days with zero withdrawal, only a return to baseline pain. I resumed use post-procedure because of the value it provided. I only know what it is because my pain Rx was stopped against my will, a risk I also accepted for the benefits of use.
3
20
193
Regulate California Now retweeted
Replying to @60Minutes
Of course they interviewed him. The guy who makes $750/hr plus as an “expert witness” in product liability cases. He makes money when these things go to court. He and his organization (PROP) spearheaded the 2016 CDC Prescribing Standards that lead to millions of functional, responsible, successful disabled persons losing their pain medication. Some committed suicide, others became much more disabled. Many moved to kratom and now he wants to attack that too. But he’s super OK with Suboxone, which is harder to stop and taper than botanical kratom and comes with major risk of severe tooth decay, the one part of your body medical insurance won’t cover, nor can immunocompromised patients at elevated risk of respiratory illness mask during a dental procedure. He’s a vampire feeding on the lives of disabled people like me and getting high on his drug of choice: attention.
1
14
69
995
Regulate California Now retweeted
Replying to @60Minutes
Friendly reminder: 60 Minutes is a profit-driven entertainment show heavily funded by pharmaceutical industry ads. A 2023 FDA complaint accused 60 Minutes of disguising an unlawful Wegovy ad as journalism after the broadcast featured only doctors on the drugmaker’s payroll.
1
5
15
119
Regulate California Now retweeted
Here is the other part of this mass tort playbook of the grieving parent. They're priming the jury. See when you put the "poor kratom addict" as a victim, even if they died with 20 drugs in their system, and you portray the typical kratom user as selfish people who don't care about grief of a parent, the jury will be less likely to care about the person losing access to kratom. They did this with Rx opioids, they're using the same playbook.
I might fall out of my chair if one single pro Kratom radical expresses sadness or condolences to the parents of young people whose death certificates say they died solely from Kratom opioids. But no—they’re going to talk about their own pain instead.
6
21
3
73
2,004
Regulate California Now retweeted
When the pandemic hit, virtual options for work and medical care sprang up overnight The type of accommodations disabled people begged for were suddenly available We watched in awe as the world adapted, and then in despair as it threw those adaptations away for “back to normal”
15
484
8
1,874
16,593
Regulate California Now retweeted
This is all part of the litigation narrative. The mass tort playbook. The moral shield of the grieving parent. Nobody’s allowed to question it and nobody’s pain can compare. Well done, Paul. I’m sure the lawyers are so proud of you.
I might fall out of my chair if one single pro Kratom radical expresses sadness or condolences to the parents of young people whose death certificates say they died solely from Kratom opioids. But no—they’re going to talk about their own pain instead.
4
13
3
41
1,163
Regulate California Now retweeted
You're right. Same playbook. Call it heroin. Say it's handed out like candy. Say it's causing an opioid crisis. Say the industry is causing a huge spike in addiction, which was never true even for Rx opioids. Get some third party litigation funding. Get some grieving parents for astroturf orgs that you attack if anyone dare to question the actual cause of death of their kids. Make some documentaries, some streaming Hulu and Netflix series, prime that jury by buying some media, push it out every day all day, then file those mass tort cases, petition to have it in an MDL, celebrate your win while millions are harmed. Glad to hear you admit it's the same playbook.
2
7
48
439
Regulate California Now retweeted
“Kratom Opioids” is akin to Andrew Kolodny calling oxycodone heroin pills and Kolodny is involved in the manufactured kratom epidemic I’m not sure where Paul came from but Paul is paid to generate fear about a plant They’re all funded Not one of them is generating fear without compensation
All those seemingly obsessed because I’m talking about the dangers of Kratom Opioids. Ready for them to tell me this text message from yesterday isn’t real. The video interviews are being set and you will hear the harrowing details from the mothers. @kratomwatch @UAFentanyl
8
26
2
74
1,735
Regulate California Now retweeted
publiclawlibrary.org/surge-i… We actually saw in opioid litigation, those astroturf orgs filled with expert witnesses encouraging these false claims. We will see the same with kratom litigation.
2
13
2
29
1,146
Regulate California Now retweeted
Here's an article from Oct 2015 which talks about the whole controversy: teapawt.net/yancykm/status/1116742…
Replying to @yancykm
"PROP’s Kolodny worked under CDC director Tom Frieden when Frieden was commissioner of the New York City Health Department." insidesources.com/dysfunctio…
3
6
1
11
Regulate California Now retweeted
None of these anti-kratom activists woke up one day and decided to vilify this plant. They’re being funded by third-party investors and you’ll never know who those investors are. Right now, they’re generating fear and priming potential jurors for God only knows how many lawsuits against kratom manufacturers. Addiction nonprofits like Shatterproof and FedUp are also part of this anti-kratom movement. They all have something to gain from this war on kratom, much like what we witnessed during the manufactured opioid crisis. This is about lawsuits, pushing kratom consumers toward the highly addictive opioid Suboxone, and finding ways to justify the continued use of opioid settlement funds. And where is the evidence that pure kratom leaf alone is causing these deaths? Why aren’t we seeing the full toxicology and autopsy reports? What other substances were involved? Same playbook used in the manufactured opioid epidemic
13
48
7
157
3,751
Regulate California Now retweeted
I trust the science over everything. Paul, I have tremendous compassion for families who have lost loved ones. Nobody should dismiss their grief. But personal tragedy, regardless of how heartbreaking, does not replace controlled clinical research, pharmacology, toxicology, or an objective determination of causation. Let’s examine what the actual scientific evidence tells us about botanical kratom. 1. FDA-Commissioned Single Ascending Dose Study (2026) FDA investigators conducted a randomized, double-blind study involving 40 participants, administering botanical kratom at doses of 1, 3, 8, 10, and 12 grams. There were ZERO deaths and ZERO serious adverse events. Nausea, vomiting, and somnolence occurred. At 12 grams, researchers also observed increased drug-liking effects. These findings are important and should not be ignored. Published research: pubmed.ncbi.nlm.nih.gov/4183… 2. Huestis et al. — Randomized, Double-Blind Clinical Trial (2026) This controlled study involved 116 participants and evaluated standardized botanical kratom in single doses and 15 consecutive daily doses. Results: • Zero deaths. • Zero serious adverse events. • Generally good tolerability at tested doses. • No evidence of meaningful withdrawal or abuse potential under the study conditions. The researchers concluded that the standardized botanical preparation was safe and well tolerated at the tested doses. pubmed.ncbi.nlm.nih.gov/4148… 3. Prevete et al. — Human Mitragynine Safety Study (2025) Researchers evaluated mitragynine at doses ranging from 5 to 40 mg in 15 healthy volunteers. Findings included: • No statistically significant changes in vital signs. • Mild, transient adverse effects. • Generally favorable acute tolerability through 40 mg. The highest dose did produce some undesirable psychological effects, reinforcing why dosage matters. pubmed.ncbi.nlm.nih.gov/3972… 4. Human Abuse-Potential Research (2026) Another peer-reviewed analysis of the 116-participant clinical trial examined subjective drug effects and opioid withdrawal measures. Researchers reported no serious adverse events, generally mild abuse-related adverse events, and no clinically meaningful withdrawal on the scales used at the tested doses. pubmed.ncbi.nlm.nih.gov/4214… Now, let’s address something critically important. Botanical kratom, standardized mitragynine extracts, and manufactured products containing pharmacologically elevated concentrations of 7-hydroxymitragynine are NOT interchangeable. They have different chemical profiles, different pharmacological characteristics, and potentially very different risk profiles. When someone attributes a death to “kratom,” scientific integrity requires examining the actual product, its alkaloid composition, toxicology findings, other substances involved, medical history, and whether causation can genuinely be established. Even the FDA acknowledges that kratom-associated fatalities frequently involve other substances and that kratom’s contribution is often unclear. None of these clinical studies establishes that kratom is harmless, and longer-term research remains necessary. But the evidence deserves to be evaluated objectively rather than dismissed because it conflicts with someone’s narrative. I support rigorous manufacturing standards, validated analytical testing, appropriate regulatory pathways, responsible labeling, and continued clinical research. I also support investigating every credible adverse event. What I will not support is conflating botanical kratom with highly concentrated 7-OH products or replacing scientific evidence with emotional arguments. And the public deserves decisions grounded in reproducible science rather than rhetoric. Science should determine public health policy. Not personal attacks, political pressure, or competing commercial interests. #Kratom #KratomScience #PublicHealth #FDA #ClinicalResearch #ConsumerSafety
I trust the moms who lost kids to Kratom, not the “philosophers” bending themselves into pretzels trying to defend big Kratom.
2
7
31
907
Regulate California Now retweeted
A package says “kratom.” But what does it actually contain?​ As #kratom products & regulations evolve, labels may not tell the whole story. Our new blog explores how laboratory testing can help investigators move from product claims to analytical evidence: okt.to/uIQn8s
2
5
1
9
318